LONDON (Alliance News) - Specialist medtech company ANGLE PLC Monday said the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia has published results of its work evaluating the potential for ANGLE's Parsortix system to be used in single-cell analysis for breast cancer.
The Sidney Kimmel Cancer Center has successfully tested the Parsortix system in combination with the single-cell analysis DEPArray system to isolate single cancer cells from blood samples spiked with cultured breast cancer cells.
The team proved the ability to manipulate the individual cancer cells from the Parsortix system and to correctly identify two breast cancer related genes (oestrogen receptor alpha (ESR1) and p53) on the cells using standard PCR analysis techniques, ANGLE said.
It added that work will now focus on molecular analysis in specified disease status and treatment settings to better identify clinical applications for more effective treatment of women with metastatic breast cancer.
"The use of single cells is emerging as a powerful approach to molecular analysis in oncology. The Parsortix system has the ability to advance molecular testing, study cancer heterogeneity and apply concepts of precision medicine to breast cancer patients' care," Director of the Jefferson Breast Care Center Dr Massimo Cristofanilli said.
"Our aim is that the Parsortix system will provide a simple and effective way to harvest CTCs [circulating tumour cells] for mutation, gene expression and other types of molecular analysis so that there is a way to determine which drugs may benefit individual patients," ANGLE Chief Executive Andrew Newland said.
Shares in ANGLE were trading up 1.8% at 75.30 pence Monday morning.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Angle (AGL)